Haleon Recalls Two Versions of Robitussin Due to Microbial Contamination
By Denny Jacob
Haleon voluntarily recalled two versions of cough medicine Robitussin due to a microbial contamination.
The personal healthcare products provider said the recall affects eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult at the consumer level.
Haleon said the use of the affected product in immunocompromised individuals could potentially result in severe or life-threatening adverse events such as fungemia or disseminated fungal infection. In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections aren't likely to occur, it added.
Haleon said to date it hasn't received reports of adverse events related to the recall.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 24, 2024 10:43 ET (15:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth